#ICANFauciEmails Hit Mainstream; TX & FL Rock Cruise Lines; Dr. Mike Yeadon Exposes Possible Covid Fraud; Utah Family Devastated By Covid Vaccine Guests: Cherie Romney & Dr. Mike Yeadon #FauciEmails #FauciLeaks #Fauci #TuckerCarlson #Texas #Covid19 #EverestRomney #MikeYeadon ORIGINAL AIR-DATE: June 10, 2021

Ivermectin 12 MG is Used to Cure Viral care Infection. #Buy Ivermectin 12 Online and Get [ 12% OFF⭐ + Free Shipping ] World wide✈.

RNA virus infections can lead to the onset of severe diseases such as fever with haemorrhage, multiorgan failure, and mortality. The emergence and reemergence of RNA viruses continue to pose a significant public health threat worldwide with particular attention to the increasing incidence of flavivi …

Federal authorities have received over 800 reports of heart inflammation in people who received a COVID-19 vaccine, a ...

We are pleased to present highlights of our webinar with Dr Darrell DeMello, who is one of these innovative medical doctors who has treated numerous COVID-19 patients and continuously improved his protocols. Dr Darrell DeMello has considerable experience with COVID-19. So far, he has treated some 6,000 COVID-19 patients and provided prophylaxis to many more family members. Note that only highlights of the webinar are presented here. Note also that the Internet connection with India, where he is located, was poor, hence the poor quality of the video. We also expect to post shortly more details about his protocols at http://covexit.com

Microsoft Word Document

Text Document

The current pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has presented unprecedented challenges to the healthcare systems in almost every country around the world. Currently, there are no proven effective vaccines or therapeut …

Effective treatment choices to the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) are limited because of the absence of effective target-based therapeutics. The main object of the current research was to estimate the antiviral activity of cannabinoids (CBDs) against the human coronavir …

We discussed evident effects of aloe-emodin and aloe polysaccharide on the therapy of viral infections and epigenetic factor butyrate that is involved in latency and reactivation in viral infection. Furthermore we presented eight case reports of Kampo medicine with Aloe vera juice (AVJ) to virus infections. Kampo medicine with AVJ-successive ingestion demonstrates to be suitably personalized medicine for virus infections and improves gut-microbial ecosystem in host. The potential Kampo medicine with AVJ may provide fresh insights as an anti-virus medicine for homeostatic regulation in host.

The nasal cavity and turbinates play important physiological functions by filtering, warming and humidifying inhaled air. Paranasal sinuses continually produce nitric oxide (NO), a reactive oxygen species that diffuses to the bronchi and lungs to produce bronchodilatory and vasodilatory effects. Stu …

A set of evolving, cautious hunches and predictions.

Urtica dioica agglutinin (UDA) is a small plant monomeric lectin, 8.7 kDa in size, with an N-acetylglucosamine specificity that inhibits viruses from Nidovirales in vitro. In the current study, we first examined the efficacy of UDA on the replication of different SARS-CoV strains in Vero 76 cells. U …

It’s been over six weeks since Iowa dropped all state-level COVID restrictions, and surprise, surprise, hospitalized patients are down 54 percent. But if you try to Google this information, all you will see is death, dying, and it must be the end of the world because of COVID, which miraculously seems to be a cure... View Article

Compromised lung function is a feature of both infection driven and non-infective pathologies. Viral infections—including the current pandemic strain SARS-CoV-2—that affect lung function can cause both acute and long-term chronic damage. SARS-CoV-2 infection suppresses innate immunity and promotes an inflammatory response. Targeting these aspects of SARS-CoV-2 is important as the pandemic affects greater proportions of the population. In clinical and animal studies, fucoidans have been shown to increase innate immunity and decrease inflammation. In addition, dietary fucoidan has been shown to attenuate pulmonary damage in a model of acute viral infection. Direct inhibition of SARS-CoV-2 in vitro has been described, but is not universal. This short review summarizes the current research on fucoidan with regard to viral lung infections and lung damage.

‘Doctors say CDC should warn people the side effects from Covid vaccine shots won’t be a walk in the park.’ Be warned to expect severe reactions to the new COVID vaccines. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, told reporters he was not certain what is causing all the vaccine reactions. But... View Article

Nitric oxide (NO) is an important signaling molecule between cells which has been shown to have an inhibitory effect on some virus infections. The purpose of this study was to examine whether NO inhibits the replication cycle of the severe acute respiratory ...

We describe the antiviral activity of plant lectins with specificity for different glycan structures against the severe acute respiratory syndrome cor…

Countries worldwide have confirmed a staggering number of COVID-19 cases, and it is now clear that no country is immune to the SARS-CoV-2 infection. Resource-poor countries with weaker health systems are struggling with epidemics of their own and are now in a more uncertain situation with this rapid …

Nitric oxide (NO) represents a key signaling molecule in multiple regulatory pathways underlying vascular, metabolic, immune, and neurological function across animal phyla. Our brief critical discussion is focused on the multiple roles of the NO signaling pathways in the maintenance of basal physiol …

Objectives To investigate the potential efficacy of Acacia Senegal extract Gum Arabic (GA) supplementation as immunomodulatory and anti-inflammatory dietary intervention among newly diagnosed COVID 19 Sudanese patients. To study the effect of GA on the level of cytokines, TNFα, IL8, IL6 IL10, CRP and the viral load. Secondary outcomes will be the effect of GA oral intake on mortality rate and days of hospital admission. Trial design Quadruple blind, randomized placebo-controlled clinical trial Phase II & III. Prospective, two-arm, parallel-group, randomised (1:1 allocation ratio) superiority trial of oral GA among seropositive COVID-19 patients. Participants Inclusion criteria: COVID-19 infected (newly diagnosed) as proved by real-time PCR within 72 hours of PCR. Age 8-90 years Both genders Exclusion criteria: Intubated patients on parenteral treatment Allergy to Gum Arabic The study will be conducted in COVID Isolation Centres and Soba University Hospital Khartoum State Sudan. Intervention and comparator Experimental: Intervention Group This arm will receive 100% natural Gum Arabic provided in a powder form in 30-grams-dose once daily for four weeks Placebo Comparator: Control group: This group will be provided with pectin powder provided as one-gram-dose once daily for four weeks Both GA and placebo will be in addition to standard care treatment based on local clinical guidelines. Main outcomes Mean change from baseline score of Immune Response to end of the trial. Changes of the level of Tumor Necrosis Factor (TNFα), interleukin IL8, IL6, and IL10 from the baseline values (Four weeks from the start of randomization). Mortality rate: The percentage of deaths among COVID 19 patients received Gum Arabic compared to placebo (Four weeks from the start of randomization]). Randomisation Randomization (1:1 allocation ratio) and will be conducted using a sequence of computer-generated random numbers by an independent individual. Each participating centre will be assigned a special code generated by the computer. The randomization will be kept by the PI and a research assistant. Blinding (masking) Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Numbers to be randomised (sample size) 110 eligible patients will be randomly assigned to either GA (n=55) or placebo (n=55) groups. Trial Status Protocol Version no 2, 30th June 2020. Recruitment will start on 15th September 2020. The intended completion date is 15th January 2021. Trial registration ClinicalTrials.gov Identifier: NCT04381871 . Date of trial registration: 11 May 2020. Full protocol The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.